CDMO Neuland Laboratories announced module one of a new commercial peptide plant at its Bonthapally campus will be operational by summer, adding thousands of liters of SPPS and LPPS reactor capacity. The first module reportedly secured approximately $30 million in firm commitments and will scale from clinical to multi‑ton commercial volumes. Neuland cited GLP‑1 manufacturing as a major driver of peptide capacity demand and said the facility is designed for further expansion with additional modules planned. The company also plans R&D and manufacturing headcount increases to support client programs. The investment aims to relieve bottlenecks for innovator and emerging biotech peptide programs and to position Neuland as a strategic commercial supplier in an increasingly capacity‑constrained market.